Logo

Novartis' Mayzent (siponimod) Receives EC's Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease

Share this

Novartis' Mayzent (siponimod) Receives EC's Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease

Shots:

  • The EC’s approval is based on P-III EXPAND study assessing Mayzent vs PBO in patients with SPMS with active disease defined as patients with relapses in the two years prior to the study and/or presence of Gd-enhancing T1 lesions at baseline
  • Results in patients with active disease & in overall population: reduction in three‑month and six‑month CDP (31% and 37% & 21% and 26%) respectively; 79% reduction in T2 lesion volume; 55% reduction in ARR; patients free from Gd enhancing lesions (89% vs 67%); from T2 lesions (57% vs 37%)
  • Mayzent is a sphingosine 1-phosphate receptor modulator- selectively targeting S1P1 and S1P5 receptors and has received the US FDA’s & TGA’s approval in Mar & Nov’2019 respectively

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Business today


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions